An Open-Label Treatment Protocol to Provide Continued ACH-126,443 [elvucitabine] to Subjects of Previous Achillion-Sponsored Phase 1 and 2 Studies in Chronic Hepatitis B Infection

Trial Profile

An Open-Label Treatment Protocol to Provide Continued ACH-126,443 [elvucitabine] to Subjects of Previous Achillion-Sponsored Phase 1 and 2 Studies in Chronic Hepatitis B Infection

Discontinued
Phase of Trial: Phase III

Latest Information Update: 25 Aug 2009

At a glance

  • Drugs Elvucitabine (Primary)
  • Indications Hepatitis B
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 25 Aug 2009 Planned end date (1 May 2003) added as reported by ClinicalTrials.gov.
    • 25 Aug 2009 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 22 Oct 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top